CDX2 and neoplasm: As listed in Table 1, when tumour origin (determined by the Krt7/20-CDX2 expression profile) was taken into account for subclassifying patients into two groups, no significant difference was noted with respect of age at diagnosis (p = 1), gender (p = 1), tumour differentiation (p = 0.313), TNM classification (T, p = 0.339; N, p = 1; M, p = 0.479), tumour stage (p = 0.847) and treatment (p = 0.062).